The global rituximab biosimilars market size was valued at USD 2.37 billion in 2023 and is projected to grow at a CAGR of 15.7% during the forecast period of 2024-2032 to reach a value of USD 8.81 billion by 2032. The market growth can be attributed to the increasing prevalence of autoimmune diseases, cancer, and the rising demand for cost-effective alternatives to branded biologics.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Biosimilar drugs possess a close resemblance with biological drugs. These drugs are exact copies of the original medications manufactured by the company. Biosimilar drugs have minimal therapeutic costs and thus provide easy accessibility to everyone for treatment.
Rituximab was licensed as Rituxan in 1997 by the United States. This was subsequently approved in 1998 by European Union as MabThera.
The reference Rituximab is approved by the European Medicine Agency for treating several types of lymphomas and leukemias. It is a chimeric anti-CD20 monoclonal antibody typically used to treat chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Rituximab is primarily administered by subcutaneous bolus injection or through an intravenous infusion.
Currently, three biosimilar rituximab products are approved by the European Medicines Agency. The first biosimilar, CT-P10 (Truxima), was approved by EMA in 2017. This drug was approved for treating all the indications as the reference biological drug.
GP2013 (Rixathon), a second biosimilar was approved by EMA for the treatment of rheumatoid arthritis. The third approved biosimilar for rituximab is Ruxience, primarily used for treating lymphoma and leukemia.
Rituximab possesses the B-cells destroying mechanism and is used to treat disorders consisting of overconcentration of B cells. Rituximab destroys B cells and is used to treat diseases characterised by an excessive number of B cells, overactive B cells or dysfunctional B cells. This includes many lymphomas, leukemia, transplant rejection, and autoimmune disorders.
The pharmacokinetics of rituximab is very complex. The ELISA (Enzyme-Linked Immune Sorbent Assay) measures rituximab concentrations. These analytical tests incorporate the monoclonal antibodies targeted against the idiotype in a molecule. The patient’s body’s rituximab levels are affected by ethnicity, type, area, and size of a tumour.
According to the rituximab biosimilars market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Rituximab Biosimilars Market Breakup by Product Type
Rituximab Biosimilars Market Breakup by Indication Type
Rituximab Biosimilars Market Breakup by Distribution Channels
Rituximab Biosimilars Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The key factor driving the growth of the rituximab biosimilars market is the rising prevalence of non-Hodgkin’s lymphoma. This lymphoma affects the white blood cells and hence, the weakening of the immune system.
According to World Health Organisation, more than 5,00,00 new cases were diagnosed with NHL in 2020. In the United States, non-Hodgkin’s lymphoma accounts for nearly 4% of cancer cases. Thus, this rising incidence of non-Hodgkin’s lymphoma is anticipated to generate significant demand for the rituximab biosimilars market over the forecast period.
Pharmaceutical companies are tremendously working on inventing new rituximab biosimilar drugs. Increased acquisitions and collaborations among top firms are also driving the market growth. For Example, in 2020, Teva pharmaceuticals and Celltrion Healthcare Co. announced the launch of Truxima, a biosimilar for treating Rheumatoid Arthritis.
The additional factors stimulating the development of the market include increased government initiatives, optimal biosimilar costs, and a rise in R&D expenditure in biopharmaceutical companies.
The expansion in healthcare accessibility, rising incidence of chronic disorders, and increased ageing population are also expected to boost the rituximab biosimilars market size.
Fewer drug approvals, stringent government regulations, and lack of awareness are the suspected reasons hindering the growth of this market. The high costs of biosimilars are also responsible for the slow growth of the market.
North America is responsible for the maximum share in the rituximab biosimilars market due to the American government's significant expenditure in the health sector. The Middle East and Africa is the fastest growing market in this region due to the escalating clinical trials in this sector.
Rituximab is a monoclonal antibody primarily targeted against the CD20 antigen of B cells. This is used for treating all types of non-Hodgkin’s lymphomas. Rituximab is generally prescribed as a monotherapy or in combination with the traditional chemo-targeted medications. It also treats many indications, including lymphocytic leukaemia, B-cell, and follicular lymphoma.
The regulatory authorities have approved only a few numbers of biosimilars to be used for treatment purposes. CT-P10, GP2013, and Ruxience are the three biosimilars of rituximab approved by the FDA for rheumatological and oncological indications. All these biosimilars are intravenous and marketed under different product names.
The biosimilars marketed by Celltrion under CT-P10 are Ritemvia, Truxima and Blitzima. The GP2013 rituximab biosimilar includes Riximyo and Rixathon, which are sold by Sandoz. The recently approved Ruxience is being marketed by Pfizer. All these rituximab reference drugs can be incorporated as a monotherapy or a combination of the targeted therapies.
European Medicine Agency has also approved more than twenty biosimilars, comprising the biosimilars of monoclonal antibodies. Rituximab is a monoclonal antibody broadly used in various disciples from nephrology, haematology, rheumatology, and oncology.
With the expiry of the currently available rituximab patents, there is a need for the development of new biosimilars. Scientists are also investigating the potential applications of rituximab biosimilars in inflammation. This invention of new biosimilars and novel plausible applications will help boost the growth of the rituximab biosimilars market.
Rituximab is generally incorporated with methotrexate to treat moderate to severe RA in adult patients. Rituximab is also subsequently approved for treating microscopic polyangiitis and granulomatosis with polyangiitis. With the new advancements, rituximab is the first-line drug in USA and Europe.
The invention and development of novel biosimilars are essential to delivering a potent and cost-effective therapy. Thus, these economic benefits will help augment the better accessibility of healthcare services. The new targeted rituximab biosimilar therapies will push the development of the rituximab biosimilars market during the forecast period.
A biosimilar must be significantly similar to its original reference product in terms of efficacy and safety. The exploratory and confirmatory clinical trials are being done to establish similarity with the reference product.
Rituximab is primarily used for treating follicular lymphoma and rheumatoid arthritis. Thus, the trials for rituximab biosimilars were conducted mainly on patients with FL and RA indications.
The clinical trials for biosimilars are a bit different from their biological ones. In biosimilar trials, there is an exemption for in-vivo clinical studies. Pharmacological and pharmacokinetic studies are done to ensure the efficacy and safety of the newly developed product relative to the reference product. The final step of rituximab biosimilar drugs involves the comparison of their PK and PD value with the RMP.
The two approved rituximab biosimilars are GP2013 and CT-P10, successfully passed the last phase of clinical trials. The Phase III study for GP2013 was done on patients with follicular lymphoma, while CT-P10 tests were performed on patients with rheumatoid arthritis.
Apart from the three approved rituximab biosimilars, five more potential biosimilars are in the last stage of clinical development. The approval of these biosimilars will lead to the rituximab biosimilars market expansion.
Out of the five biosimilars, the approved proposal for MabionCD20 has been sent to the European Medicine Agency, while the rest four are still in the last stage of clinical testing.
The rituximab and its biosimilars have significantly influenced patient outcomes and have facilitated growth in the healthcare sector. These drugs in the developmental stage seem to provide magnificent advantages regarding social and economic inputs.
The proposed rituximab biosimilars are in the last stage of clinical trials and under observation by the regulatory authorities. The invention of novel rituximab biosimilars will help in better treatments at lesser costs.
These novel targeted therapies seem to grab the attention of key companies and investors, which will directly influence the advancements in this sector. This will help enable patient access and growth of the rituximab biosimilars market.
The report gives an in-depth analysis of the key players involved in the rituximab biosimilars market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Product Type
|Breakup by Indication Type
|Breakup by Distribution Channels
|Breakup by Region
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Rituximab Biosimilars Overview
4.1 Drug Overview
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Rituximab Biosimilars Market
6.1 Global Rituximab Biosimilars Market Overview
6.2 Global Rituximab Biosimilars Market Analysis
6.2.1 Market Overview
18.104.22.168 Global Rituximab Biosimilars Market Historical Value (2017-2023)
22.214.171.124 Global Rituximab Biosimilars Market Forecast Value (2024-2032)
6.3 Global Rituximab Biosimilars Market by Product Type
6.3.1 Market Overview
6.4 Global Rituximab Biosimilars Market by Indication Type
6.4.1 Market Overview
126.96.36.199 Non-Hodgkin’s Lymphoma
188.8.131.52 Chronic Lymphocytic Leukemia
184.108.40.206 Rheumatoid Arthritis
6.5 Global Rituximab Biosimilars Market by Distribution Channels
6.5.1 Market Overview
220.127.116.11 Hospital-Based Pharmacies
18.104.22.168 Online Pharmacies
22.214.171.124 Retail Pharmacies
6.6 Global Rituximab Biosimilars Market by Region
6.6.1 Market Overview
126.96.36.199 North America
188.8.131.52 Asia Pacific
184.108.40.206 Latin America
220.127.116.11 Middle East and Africa
7 North America Rituximab Biosimilars Market
7.1 Market Share by Country
7.2 United States of America
7.2.1 Historical Trend (2017-2023)
7.2.2 Forecast Trend (2024-2032)
7.3.1 Historical Trend (2017-2023)
7.3.2 Forecast Trend (2024-2032)
8 Europe Rituximab Biosimilars Market
8.1 Market Share by Country
8.2 United Kingdom
8.2.1 Historical Trend (2017-2023)
8.2.2 Forecast Trend (2024-2032)
8.3.1 Historical Trend (2017-2023)
8.3.2 Forecast Trend (2024-2032)
8.4.1 Historical Trend (2017-2023)
8.4.2 Forecast Trend (2024-2032)
8.5.1 Historical Trend (2017-2023)
8.5.2 Forecast Trend (2024-2032)
9 Asia Pacific Rituximab Biosimilars Market
9.1 Market Share by Country
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
9.4.1 Historical Trend (2017-2023)
9.4.2 Forecast Trend (2024-2032)
9.5.1 Historical Trend (2017-2023)
9.5.2 Forecast Trend (2024-2032)
9.6.1 Historical Trend (2017-2023)
9.6.2 Forecast Trend (2024-2032)
10 Latin America Rituximab Biosimilars Market
10.1 Market Share by Country
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
11 Middle East and Africa Rituximab Biosimilars Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 United Arab Emirates
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 South Africa
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
12 Global Rituximab Biosimilars Market Dynamics
12.1 Market Drivers and Constraints
12.2 Drug Adoption Parameters
12.3 SWOT Analysis
12.4 Porter Five Forces Model
12.5 Key Demand Indicators
12.6 Key Price Indicators
12.7 Industry Events, Initiatives, and Trends
12.8 Value Chain Analysis
13 Supplier Landscape
13.1 Innovent Biologics Inc
13.1.1 Company Overview
13.1.2 Product Portfolio
13.1.3 Demographic Reach and Achievements
13.1.4 Mergers and Acquisitions
13.2 Gedeon Richter Plc.
13.2.1 Company Overview
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.3 BioXpress Therapeutics SA
13.3.1 Company Overview
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.4 Teva Pharmaceutical Industries Ltd.
13.4.1 Company Overview
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.5 Takeda Pharmaceutical Company Limited
13.5.1 Company Overview
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.6 Sandoz International GmbH (Novartis)
13.6.1 Company Overview
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.7 Zydus Lifesciences Ltd.
13.7.1 Company Overview
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.8 Hetero Drugs Limited
13.8.1 Company Overview
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.9 Dr Reddy's Laboratories Ltd
13.9.1 Company Overview
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.10 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
13.10.1 Company Overview
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.11 Zenotech Laboratories
13.11.1 Company Overview
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.12 Napp Pharmaceuticals Limited
13.12.1 Company Overview
13.12.2 Product Portfolio
13.12.3 Demographic Reach and Achievements
13.12.4 Mergers and Acquisitions
13.13 Mundipharma International Limited
13.13.1 Company Overview
13.13.2 Product Portfolio
13.13.3 Demographic Reach and Achievements
13.13.4 Mergers and Acquisitions
14 Pricing Models and Strategies (Additional Insight)
14.1 Cost Model
14.1.1 Manufacturing Cost Analysis
14.1.2 Procurement Cost Analysis
14.2 Pricing Strategies
14.2.1 Competitor Pricing Analysis
14.2.2 Key Assessment of Product Attributes
14.2.3 Pricing Benchmark
15 Global Rituximab Biosimilars Market- Distribution Model (Additional Insight)
15.2 Potential Distributors
15.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
The factors stimulating the development of the market are increased government initiatives, optimal biosimilars costs, and a rise in R&D expenditure in biopharmaceutical companies.
Fewer drug approvals, stringent government regulations, and lack of awareness are the suspected reasons for hindering the growth of this market.
Based on the product type, the market is categorised into blitzima and rixathon, among others.
Based on the indication, the market is divided into non-Hodgkin’s Lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, among others.
The distribution channels are hospital-based pharmacies, retail pharmacies, and online pharmacies.
Based on the region, the market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
The trade name for rituximab is Rituxan.
Truxima is the biosimilar of the rituximab reference drug.
A biosimilar is a copy of a biologic medicine that is similar, but not identical, to the original drug.
Biosimilars are available at low costs and thus, have the potential to enhance treatment accessibility.
Rituximab and its biosimilars are primarily used to treat rheumatoid arthritis, lymphoma, and leukaemia.
The major companies involved are Innovent Biologics Inc, Gedeon Richter Plc., BioXpress Therapeutics SA, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sandoz International GmbH (Novartis), Zydus Lifesciences Ltd., Hetero Drugs Limited, Dr Reddy's Laboratories Ltd, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Zenotech Laboratories, Napp Pharmaceuticals Limited, and Mundipharma International Limited, among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.